With Little Product Overlap, Pfizer/Wyeth Commercial Synergies Are Subtle
Executive Summary
Commercial synergies clearly are not driving Pfizer's pending acquisition of Wyeth. The companies have said that their marketed products are largely complementary with little overlap, and analysts agree